This Is The New Pricing Story For Nebius

Petri Dish Reports
1.89K Followers

Summary

  • Nebius Group remains a Buy as it monetizes AI infrastructure scarcity, with 2Q26 revenue up 454% YoY and EBITDA margins guided at 40%+ for FY26.
  • NBIS is leveraging a structurally supply-constrained market, achieving $20–25M/MW for core contracts and $40–50M/MW for urgent capacity, driving step-change unit economics.
  • The business model is shifting toward auction-style pricing, asset-light partnerships, and higher-margin software layers, supporting a multi-year hypergrowth and operating leverage thesis.
  • Valuation is premium at 17.5x forward EV/sales, reflecting market expectations for sustained 40–60% revenue growth and margin expansion but leaving little room for execution risk.

Close-up of office worker calculating financial data with calculator while reviewing receipts, documents, representing accounting tasks, budgeting, expense management, professional financial workflow.

Thai Noipho/iStock via Getty Images

Thesis

Overall, I’m still buy-rated on Nebius Group N.V. (NBIS) here. In my previous coverage, I’ve focused quite a bit on the customer offerings from Nebius and gone into details of the

This article was written by

Petri Dish Reports
1.89K Followers
I hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation for the rigor and challenges behind drug development, which I now bring into my work as an investor and analyst. For the past five years, I have been active in the investing space, with the last four years dedicated to working as a biotech equity analyst alongside my lab work. My focus is on identifying promising biotechnology companies that are innovating in unique and differentiated ways, whether through novel mechanisms of action, first-in-class therapies, or platform technologies with the potential to reshape treatment paradigms. By combining my lab-based scientific expertise with financial and market analysis, I aim to deliver research that is both technically sound and investment-driven. On Seeking Alpha, I plan to write primarily about the biotech sector, covering companies at different stages of development, from early clinical pipelines to commercial-stage biotechs. My approach emphasizes evaluating the science behind drug candidates, the competitive landscape, clinical trial design, and the potential market opportunity, all while balancing financial fundamentals and valuation. My goal in publishing here is to share some insights that help investors better understand both the opportunities and of course the many risks in biotech. This is a sector where breakthrough science can translate into outsized returns, but also where careful scrutiny is essential. I look forward to contributing thoughtful analysis and engaging with readers who share an interest in this dynamic and rapidly evolving space.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.